Test Catalog

Test ID: LMO2    
LIM Domain Only 2 (LMO2) Immunostain, Technical Component Only

Useful For Suggests clinical disorders or settings where the test may be helpful

Classification of lymphomas

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

For the initial technical component only immunohistochemical (IHC) stain performed, the appropriate bill-only test ID will be reflexed and charged (IHTOI). For each additional technical component only IHC stain performed, an additional bill-only test ID will be reflexed and charged (IHTOA).

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

LIM domain only 2 (LMO2) is a transcription factor that regulates vascular and hematopoietic systems and is involved in hematolymphoid neoplasia. LMO2 is preferentially expressed by germinal center B cells and may also be expressed in erythroid and myeloid precursors and in megakaryocytes. Expression has been observed in cases of lymphoblastic and acute myeloid leukemia. It is rarely expressed in mature T, natural killer, and plasma cell neoplasms and is absent from nonhematolymphoid tissues except for endothelial cells. In the diagnosis of B-cell lymphomas, LMO2 can be useful in an immunohistochemical panel to assign a germinal center phenotype.

Interpretation Provides information to assist in interpretation of the test results

This test includes only technical performance of the stain (no pathologist interpretation is performed). Mayo Clinic cannot provide an interpretation of tech only stains outside the context of a pathology consultation. If an interpretation is needed, refer to PATHC / Pathology Consultation for a full diagnostic evaluation or second opinion of the case. All material associated with the case is required. Additional specific stains may be requested as part of the pathology consultation, and will be performed as necessary at the discretion of the Mayo pathologist.


The positive and negative controls are verified as showing appropriate immunoreactivity and documentation is retained at Mayo Clinic Rochester. If a control tissue is not included on the slide, a scanned image of the relevant quality control tissue is available upon request. Contact 855-516-8404.


Interpretation of this test should be performed in the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Age of a cut paraffin section can affect immunoreactivity. Stability thresholds vary widely among published literature and are antigen-dependent. Best practice is for paraffin sections to be cut within 6 weeks.

Clinical Reference Recommendations for in-depth reading of a clinical nature

1. Natkunam Y, Zhao S, Mason DY, et al: The oncoprotein LMO2 is expressed in normal germinal-center b cells and in human b-cell lymphomas. Blood 2007, Feb 15;109(4):1636-1642

2. Blenk S, Engelmann J, Weniger M, et al: Germinal center b cell-like and activated b cell-like type of diffuse large b cell lymphoma: Analysis of molecular predictors, signatures, cell cycle state and patient survival. Cancer Inform 2007 Dec 12;3:399-420

3. Natkunam Y, Farinha P, His ED, et al: LMO2 protein expression predicts survival in patients with diffuse large b -cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol 2008 Jan 20;26(3):447-454

4. Gratzinger D, Zhao S, West R, et al: The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities. Am J Clin Pathol 2009 Feb;131(2):264-278

5. Younes SF, Beck AH, Lossos IS, et al: Immunoarchitectural patterns in follicular lymphoma: efficacy of HGAL and LMO2 in the detection of the interfollicular and diffuse components. Am J Surg Pathol 2010 Sep;34(9):1266-1276